title: A set of genes associated with the interferon-γ response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapy.
abstract: Invariant natural killer T (iNKT) cells possess potent antitumor effects after activation with a specific glycolipid antigen, α-galactosylceramide (αGalCer). A phase I-II clinical study of αGalCer-pulsed dendritic cells (DC) to activate endogenous iNKT cells was previously performed in patients with non-small-cell lung cancer (NSCLC). In this clinical trial, the patients with increased interferon-γ (IFN-γ) production (>two-fold) in PBMC after the DC treatment (good responder group) experienced a prolonged overall survival time in comparison with the poor responder group. We extended the previous study and performed a microarray-based gene expression analysis using peripheral blood CD56(+) cells and CD56(-) CD3(+) T cells from patients enrolled in the above-mentioned clinical study. We sought to identify any biomarkers associated with the immune responses in this immunotherapy trial. Six patient samples corresponding to three subjects in the good responder group and three subjects in the poor responder group were included in the microarray analysis. Genes differentially expressed between pre-treatment and post-treatment samples were selected for analysis. Subsequently, genes that were only expressed in the good responder group or poor responder group were chosen. After these procedures, four selected genes were quantified by reverse transcriptase-polymerase chain reaction in another eight patient samples, and two genes, LTB4DH and DPYSL3, were confirmed to be candidate genes for the predictor of a good immune response. The expression profile of these two genes may be associated with the responsiveness of IFN-γ production after αGalCer-pulsed DC treatment.
authors.affiliation: Department of Immunology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan.
authors.forename: Kohsuke
authors.initials: K
authors.lastname: Okita
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Motohashi
authors.forename: Ryo
authors.initials: R
authors.lastname: Shinnakasu
authors.forename: Kaoru
authors.initials: K
authors.lastname: Nagato
authors.forename: Kazuki
authors.initials: K
authors.lastname: Yamasaki
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Sato
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kitamura
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hijikata
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Yamashita
authors.forename: Kanako
authors.initials: K
authors.lastname: Shimizu
authors.forename: Shin-Ichiro
authors.initials: S
authors.lastname: Fujii
authors.forename: Osamu
authors.initials: O
authors.lastname: Ohara
authors.forename: Masaru
authors.initials: M
authors.lastname: Taniguchi
authors.forename: Isao
authors.initials: I
authors.lastname: Sakaida
authors.forename: Toshinori
authors.initials: T
authors.lastname: Nakayama
mesh_terms: D000328:Adult; D000368:Aged; D000429:Alcohol Oxidoreductases / Q000235:genetics*; D017252:CD3 Complex / Q000378:metabolism; D019002:CD56 Antigen / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D016000:Cluster Analysis; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation; D005260:Female; D005699:Galactosylceramides / Q000276:immunology; D020869:Gene Expression Profiling; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D016219:Immunotherapy, Adoptive; D007371:Interferon-gamma / Q000378:metabolism; D008175:Lung Neoplasms / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009124:Muscle Proteins / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism*
chemical_list: D017252:CD3 Complex; D019002:CD56 Antigen; C102926:DPYSL3 protein, human; D005699:Galactosylceramides; D009124:Muscle Proteins; D007371:Interferon-gamma; D000429:Alcohol Oxidoreductases; C082646:leukotriene B4 12-hydroxydehydrogenase
references.citation: Int J Cancer. 2006 Oct 15;119(8):1915-9
references.pmid: 16721812
references.citation: J Clin Oncol. 2008 Feb 20;26(6):983-94
references.pmid: 18281673
references.citation: Clin Cancer Res. 2005 Mar 1;11(5):1910-7
references.pmid: 15756017
references.citation: Nucleic Acids Res. 2003 Feb 15;31(4):e15
references.pmid: 12582260
references.citation: Neurosci Lett. 2008 Jan 17;430(3):197-202
references.pmid: 18053648
references.citation: J Clin Oncol. 2000 Nov 1;18(21):3722-30
references.pmid: 11054445
references.citation: Trends Immunol. 2002 Mar;23(3):144-50
references.pmid: 11864843
references.citation: J Clin Oncol. 2000 May;18(10):2095-103
references.pmid: 10811675
references.citation: J Biol Chem. 2004 May 21;279(21):22615-23
references.pmid: 15007077
references.citation: Eur J Immunol. 2000 Apr;30(4):985-92
references.pmid: 10760785
references.citation: Gene. 1996 Nov 21;180(1-2):157-63
references.pmid: 8973361
references.citation: Semin Immunol. 2010 Apr;22(2):97-102
references.pmid: 19939703
references.citation: Nat Genet. 2003 Jan;33(1):90-6
references.pmid: 12469123
references.citation: Arch Biochem Biophys. 2000 Feb 15;374(2):153-60
references.pmid: 10666293
references.citation: Annu Rev Immunol. 2007;25:297-336
references.pmid: 17150027
references.citation: Cancer Sci. 2008 Apr;99(4):638-45
references.pmid: 18294290
references.citation: J Exp Med. 2003 Jul 21;198(2):267-79
references.pmid: 12874260
references.citation: N Engl J Med. 2002 Jan 10;346(2):92-8
references.pmid: 11784875
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1845-51
references.pmid: 17855704
references.citation: Cancer Res. 2007 Aug 15;67(16):7901-6
references.pmid: 17699796
references.citation: Bioinformatics. 2007 Nov 1;23(21):2934-41
references.pmid: 17893089
references.citation: Nat Immunol. 2003 Dec;4(12):1164-5
references.pmid: 14639465
references.citation: J Immunol. 2009 Feb 15;182(4):2492-501
references.pmid: 19201905
references.citation: Clin Chem. 1993 Apr;39(4):561-77
references.pmid: 8472349
references.citation: Bioinformatics. 2002 Dec;18(12):1585-92
references.pmid: 12490442
references.citation: Lung Cancer. 2008 Jun;60(3):313-24
references.pmid: 18440087
references.citation: Nat Rev Immunol. 2004 Mar;4(3):231-7
references.pmid: 15039760
references.citation: Blood. 2002 Feb 15;99(4):1259-66
references.pmid: 11830474
references.citation: J Immunol. 1999 Nov 1;163(9):4647-50
references.pmid: 10528160
references.citation: Mol Neurobiol. 2003 Aug;28(1):51-64
references.pmid: 14514985
references.citation: Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6624-31
references.pmid: 18006763
references.citation: J Exp Med. 2005 Feb 7;201(3):397-408
references.pmid: 15699073
references.citation: Eur Respir J Suppl. 1996 Aug;22:90s-94s
references.pmid: 8871051
references.citation: N Engl J Med. 2004 Jan 22;350(4):379-92
references.pmid: 14736930
references.citation: Science. 1997 Nov 28;278(5343):1626-9
references.pmid: 9374463
references.citation: Science. 1988 Jun 3;240(4857):1285-93
references.pmid: 3287615
references.citation: Annu Rev Immunol. 2003;21:483-513
references.pmid: 12543936